SCHEMBL721403

SCHEMBL721403

COc1ccc2cc(C(=O)C3CCCCC3)oc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.56
ALDH1A1 P00352 6/20 0.56
HSD17B10 Q99714 5/20 0.56
HPGD P15428 5/20 0.56
RAB9A P51151 3/20 0.56
KMT2A Q03164 3/20 0.50
GAA P10253 3/20 0.50
CYP2D6 P10635 2/20 0.50
GLA P06280 2/20 0.50
CYP1A2 P05177 2/20 0.49
MEN1 O00255 1/20 0.49
RECQL P46063 1/20 0.49
NPC1 O15118 2/20 0.49
MAPT P10636 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
SLC16A3 O15427 1/20 0.48
MAOB P27338 1/20 0.48
KDM2B Q8NHM5 3/20 0.47
CA2 P00918 1/20 0.47
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL178096 0.77 ALDH1A1 (0.66) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL31367874 0.77 CYP2D6 (0.59) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL1287537 0.77 ALDH1A1 (0.66) KDM4EALDH1A1HSD17B10HPGDRAB9A
Hydrochloric Acid SCHEMBL11747973 0.76 ALDH1A1 (0.64) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL9251599 0.76 CYP2D6 (0.58) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL4450673 0.76 KDM4E (0.67) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL719422 0.74 CYP2C19 (0.64) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL29233574 0.73 RAB9A (0.58) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL6240000 0.73 CYP2D6 (0.70) KDM4EALDH1A1HSD17B10HPGDRAB9A
SCHEMBL5510096 0.73 CYP2D6 (0.49) KDM4EALDH1A1HSD17B10HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885HSD17B10 691/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885HSD17B10 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.